Embodiment of Power: Representations of Women in Relief Panels from the Sebasteion at Aphrodisias as Personifications of Roman Imperial Influence

The Sebasteion at Aphrodisias is a large temple complex located in present-day Turkey. It was constructed over a 40 year period during the Julio-Claudian dynasty (c. 20-60 C.E.). The Sebasteion was dedicated to the Julio-Claudian emperors, the Greek goddess Aphrodite, and the people of Aphrodisias, and therefore exemplifies Roman imperial power in the Greek East. Women are popular subjects in the114 Sebasteion reliefs and statues, but previous scholarship has neglected to examine the intersection of patriarchy, status, and imperialism in the context of a free but incorporated city, such as Aphrodisias. This thesis argues that the imperial agenda of the early Roman Empire was reinforced by patriarchal representations of women as both agents and objects of the Roman Empire’s power in relief panels of Claudius and Britannia, Nero and Armenia, Claudius and Agrippina, Aphrodite and Roma, Augustus and Nike, and the Emperor and People or Senate

High-throughput profiling of the serum N-glycome on capillary electrophoresis microfluidics systems: toward clinical implementation of glycoHepatoTest

We developed a 3 h procedure for preparing serum N-glycans and labeling them with 8-aminopyrene-1,3,6-trisulfonic acid (APTS) by sequential addition of reagents to the serum and incubation in a polymerase chain reaction (PCR) thermocycler. Moreover, we succeeded in analyzing these samples by capillary electrophoresis on three commercial microfluidics-based platforms: the MCE-202 MultiNA, the 2100 Bioanalyzer, and a modified prototype of the eGene system which were originally designed for nucleic acid separation and detection. Although these instruments use short separation channels, our technical improvements made it possible to reliably measure the N-glycans constituting GlycoHepatoTest. This test comprises a panel of biomarkers that allows follow-up of liver fibrosis patients starting from the early stage. In this way and for the first time, we demonstrate a clinical glycomics assay on an affordable, robust platform so that clinical chemistry laboratories can exploit glycomics in the diagnosis and monitoring of chronic liver disease. Another potential application is the rapid screening of the N-glycosylation of recombinant glycoproteins produced for pharmaceutical use